Lorbrexen 100 mg (Lorlatinib) Tablets

Lorlatinib 100 mg is a targeted anticancer medicine used for adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). It is intended for tumors in which anaplastic lymphoma kinase (ALK) positivity has been confirmed through appropriate testing.

Key Uses

• Treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC)
• Targeted treatment for tumors driven by abnormal ALK signaling
• May be used in patients who require an ALK-directed systemic therapy
• Can provide an option for patients whose ALK-positive NSCLC has progressed after previous ALK inhibitor therapy, depending on the applicable treatment guideline and local prescribing information.

Therapeutic Effects

Lorlatinib is designed to inhibit abnormal ALK signaling that contributes to the growth and survival of ALK-positive cancer cells. By blocking the activity of ALK and related kinase signaling, the medicine can interfere with pathways involved in tumor-cell proliferation and survival.

Lorlatinib is also designed to reach the central nervous system, which is clinically relevant in ALK-positive NSCLC because metastatic disease may involve the brain. The expected therapeutic effect is disease control through inhibition of ALK-driven cancer signaling rather than a general cytotoxic effect on all rapidly dividing cells.

Important: Lorlatinib is a prescription anticancer medicine and should be used only under the supervision of an appropriately qualified oncology professional.

Active Ingredient

Lorlatinib — 100 mg

Each 100 mg film-coated tablet contains 100 mg of lorlatinib as the active pharmaceutical ingredient.

Tablet Core

Commonly listed inactive ingredients include:

• Microcrystalline cellulose
• Dibasic calcium phosphate anhydrous
• Sodium starch glycolate
• Magnesium stearate

Film Coating

The film coating may contain:

• Hypromellose / Hydroxypropyl methylcellulose (HPMC)
• Lactose monohydrate
• Macrogol 4000 / PEG 3350
• Triacetin
• Titanium dioxide
• Black iron oxide
• Red iron oxide

Excipient note: The 100 mg film-coated tablet contains lactose monohydrate; individuals with lactose intolerance or other relevant dietary restrictions should discuss the product with their healthcare professional.

Recommended Adult Dose

The recommended dose of lorlatinib is 100 mg orally once daily. It may be taken with or without food and is generally continued until disease progression or unacceptable toxicity, according to the treating physician's assessment.

How to Take Lorlatinib 100 mg

• Take one 100 mg tablet once daily, unless your oncologist has prescribed a different dose.
• Take the tablet at approximately the same time every day.
• Lorlatinib can be taken with or without food.
• Swallow the tablet whole with water.
• Do not chew, crush, or split the tablet.
• Do not use a tablet that is broken, cracked, or otherwise damaged.

Missed Dose

If a scheduled dose is missed, take it when remembered unless the next scheduled dose is due within 4 hours. If the next dose is within 4 hours, skip the missed dose and return to the normal schedule.

Do not take two doses at the same time to compensate for a missed dose.

If Vomiting Occurs

If vomiting occurs after taking lorlatinib, do not take an additional tablet. Continue with the next dose at the regularly scheduled time.

Dose Adjustments

Lorlatinib dosage may need to be reduced or temporarily interrupted when clinically significant adverse reactions occur. Current prescribing information lists 75 mg once daily as the first dose reduction and 50 mg once daily as the second dose reduction. Patients unable to tolerate 50 mg once daily may require permanent discontinuation. These changes should be made only by the treating physician.

Important Administration Advice

Lorlatinib should be prescribed after confirmation of ALK-positive NSCLC using an appropriate validated testing method. Because this is a specialized anticancer therapy, treatment should be initiated and monitored by a healthcare professional experienced in oncology.

Recommended SEO page heading:
Lorlatinib 100 mg Uses, Composition, Dosage & Administration

This wording naturally captures searches around lorlatinib uses, lorlatinib 100 mg dosage, lorlatinib composition, ALK-positive NSCLC treatment, and lorlatinib tablets without keyword stuffing.